依酚氯铵(Edrophonium Chloride) - 药物靶点：AChE_在研适应症：重症肌无力，神经肌肉阻滞逆转_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Edrophonium chloride (JP17/USP/INN)、Antirex、Enlon

+ [3]

靶点

AChE

作用机制

AChE抑制剂(乙酰胆碱酯酶抑制剂)、肌松拮抗剂

治疗领域

肿瘤免疫系统疾病神经系统疾病+ [1]

在研适应症

重症肌无力神经肌肉阻滞逆转

非在研适应症-

原研机构

VJGJ, Inc.

在研机构

KYORIN Pharmaceutical Co., Ltd.济南博世医药科技有限公司

非在研机构

PAI Holdings LLC

最高研发阶段批准上市

首次获批日期

美国 (1951-05-03),

重症肌无力

最高研发阶段(中国)临床1期

特殊审评-

登录后查看时间轴

结构

分子式C10H16ClNO

InChIKeyBXKDSDJJOVIHMX-UHFFFAOYSA-N

CAS号116-38-1

关联

3

项与依酚氯铵相关的临床试验

CTR20182086 / Not yet recruiting临床1期

依酚氯铵注射液用于拮抗罗库溴铵注射液残留神经肌肉阻滞的安全性、药动学及有效性临床研究

主要目的：研究依酚氯铵注射液在全身麻醉手术后患者中与硫酸阿托品注射液同时单次静脉注射给药的药代动力学特征，并与国外文献数据进行对比分析，为借鉴原研产品说明书的用法用量提供药代动力学依据。次要目的：评估依酚氯铵注射液的安全性；初步评估依酚氯铵注射液拮抗残留神经肌肉阻滞的疗效。

开始日期-

申办/合作机构

济南博世医药科技有限公司

JPRN-UMIN000022557 / CompletedIIT

Edrophonium challenge test for dystonia - Edrophonium test for dystonia

开始日期2012-06-01

申办/合作机构-

NCT00748059 / Completed临床1期IIT

The Pathophysiology of Orthostatic Hypotension

The purpose of this study is to determine the cause of low blood pressure in selective patients who have problems with their involuntary (autonomic) nervous system. These patients frequently have had symptoms throughout their life, and their disorder might have a genetic basis. The biochemical, physiological and pharmacological procedures in this study should help us define the problem and perhaps lead to more effective treatment.

开始日期1996-12-01

申办/合作机构

Vanderbilt University Medical Center

100 项与依酚氯铵相关的临床结果

登录后查看更多信息

100 项与依酚氯铵相关的转化医学

登录后查看更多信息

100 项与依酚氯铵相关的专利（医药）

登录后查看更多信息

968

项与依酚氯铵相关的文献（医药）

2024-02-01·Current Drug Safety

Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade in Adults and Children: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Review

作者: Gupta, Lalit K ; Chhabra, Ridhi ; Gupta, Rachna

Background:Cholinesterase inhibitors, such as neostigmine and edrophonium, commonly used to reverse the residual effects of nondepolarizing neuromuscular blocking drugs at the end of surgery are associated with a high rate of residual neuromuscular blockade (NMB). Due to its direct mechanism of action, sugammadex is associated with rapid and predictable reversal of deep NMB. The current analysis compares the clinical efficacy and risk of postoperative nausea and vomiting (PONV) on using sugammadex or neostigmine for routine NMB reversal in adult and pediatric populations.Methods:PubMed and ScienceDirect were searched as the primary databases. Randomized controlled trials comparing sugammadex with neostigmine for routine NMB reversal in adult and pediatric patients have been included. The primary efficacy endpoint was the time from initiation of sugammadex or neostigmine to the recovery of a time-of-four ratio (TOF) ≥ 0.9. PONV events have been reported as secondary outcomes.Results:A total of 26 studies have been included in this meta-analysis, 19 for adults with 1574 patients and 7 for children with 410 patients. Sugammadex, when compared to neostigmine, has been reported to take a shorter time to reverse NMB in adults (mean difference = -14.16 min; 95% CI [-16.88, -11.43], P < 0.01), as well as in children (mean difference = -26.36 min; 95% CI [- 40.16, -12.57], P < 0.01). Events of PONV have been found to be similar in both the groups in adults, but significantly lower in children treated with sugammadex, i.e., 7 out of 145 with sugammadex versus 35 out of 145 with neostigmine (odds ratio = 0.17; 95% CI [0.07, 0.40]).Conclusion:Sugammadex is associated with a significantly shorter period of reversal from NMB in comparison to neostigmine in adult and pediatric patients. Regarding PONV, the use of sugammadex for NMB antagonism may offer a better option for pediatric patients.

2024-01-01·Internal Medicine

Unusual Presentation of Double-seronegative Myasthenia Gravis with Positive Anti-LRP4 Antibody: Diagnostic Utility of a Videofluoroscopic Swallowing Study

Article

作者: Higuchi, Osamu ; Ishihara, Shoichiro ; Takahashi, Sunao ; Oniki, Ayako ; Yanai, Kensaku ; Tomimitsu, Hiroyuki ; Soejima, Itsuki ; Matsuda, Toshiya

An 86-year-old woman was admitted to our hospital with cryptogenic progressive dyspnea and dysphagia following a tracheostomy procedure 4 months prior to presentation. She exhibited fluctuating diplopia, bilateral vocal fold paralysis, normal nerve test results, negative findings for serum anti-acetylcholine receptor and anti-muscle-specific kinase antibodies, and positive findings for anti-LDL-receptor related protein 4 (LRP4). A videofluoroscopic swallowing study (VFSS) with edrophonium revealed an improvement in bulbar paralysis. Consequently, the patient was diagnosed with double-seronegative myasthenia gravis (DSN-MG) and began immunomodulatory therapy. This case emphasizes the diagnostic challenges of bulbar-type DSN-MG and underscores the value of a VFSS with edrophonium for diagnosing this condition.

2023-01-01·Journal of the Neurological Sciences

Immune checkpoint inhibitor-related myositis and myocarditis with multiple myositis-specific/−associated antibodies

Letter

作者: Sakamoto, Naohiro ; Takazaki, Hiroshi ; Suzuki, Kazushi ; Yamazaki, Keishi ; Isa, Megumi ; Asakuma, Junichi ; Ikewaki, Katsunori ; Hongo, Yu

In recent years, immune checkpoint inhibitors (ICI) have become the standard treatments for various cancers. These drugs are monoclonal antibodies targeting mols. such as cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1), and PD-1 ligand (PD-L1). ICI activate the immune system to eliminate malignancies.Here, we report a case of myositis/myocarditis with multiple myositis-specific-antibodies (MSAs) and myositis-associated-antibodies (MAAs) during use of pembrolizumab, a PD-1 inhibitor, which improved with immunotherapy.The result of ice pack test was neg. in this case. I.v. administration of edrophonium did not improve ptosis (1-A), grip strength and upper/ lower limb muscle strength. As described above, the various tests to detect myasthenic symptoms were neg.When clinicians encounter neuroimmune disorders during ICI treatment, it is sometimes difficult to determine whether they are drugderived reactions or tumor-associated symptoms.If the symptoms are drug-derived, the ICI should be discontinued, however, if the symptoms are tumor-related, the ICI should be continued. Simultaneous-positivemultiple MSAs is suggestive of an ICI-derived autoimmune response and may be a useful insight for clinicians treating myositis during ICI use to select a more appropriate treatment.

100 项与依酚氯铵相关的药物交易

登录后查看更多信息